Home The Word Brain	My Amedeo FAQ Privacy About
	C49 + CC Journal Club For more information, please refer to our special emails from April 13 and May 19.

Urinary Tract Infection

Free Subscription Articles published in J Antimicrob Chemother Retrieve available abstracts of 37 articles: HTML format

Single Articles

February 2025
1. HUNTER CJ, Marhoffer EA, Holleck JL, Ein Alshaeba S, et al
   Effect of empiric antibiotics against Pseudomonas aeruginosa on mortality in hospitalized patients: a systematic review and meta-analysis.
   J Antimicrob Chemother. 2025;80:322-333.
   PubMed     Abstract available
   
   
   December 2024
2. ZOHAR I, Ben David D, Schwartz O, Pomerantz A, et al
   Amikacin treatment in patients with Enterobacterales bacteraemia: impact of MIC on mortality.
   J Antimicrob Chemother. 2024;79:3204-3209.
   PubMed     Abstract available
   
   
   November 2024
3. LEROY AG, Lemenand O, Thibaut S, Coeffic T, et al
   Assessment of co-resistance to antibiotics recommended for acute pyelonephritis among Escherichia coli clinical strains from community- and nursing home-acquired urinary tract infections.
   J Antimicrob Chemother. 2024 Nov 29:dkae431. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. ABBOTT IJ, Anderson CRB, van Gorp E, Wallis SC, et al
   Oral ciprofloxacin biofilm activity in a catheter-associated urinary tract infection model.
   J Antimicrob Chemother. 2024 Nov 29:dkae424. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. HERNANDEZ-LOZANO I, Aranzana-Climent V, Cao S, Matias C, et al
   Model-informed drug development for antimicrobials: translational pharmacokinetic-pharmacodynamic modelling of apramycin to facilitate prediction of efficacious dose in complicated urinary tract infections.
   J Antimicrob Chemother. 2024 Nov 16:dkae409. doi: 10.1093.
   PubMed     Abstract available
   
   
   October 2024
6. MASSIP C, Feletti L, Chagneau CV, Dumont Y, et al
   Evaluation of several routine methods for fosfomycin and mecillinam susceptibility testing of Enterobacterales urine isolates.
   J Antimicrob Chemother. 2024;79:2645-2652.
   PubMed     Abstract available
   
   
   September 2024
7. DIZI ISIK A, Akkoc G, Ergenc Z, Yilmaz S, et al
   The use of fosfomycin in infections caused by multidrug-resistant pathogens, especially pneumonia in children: a five-year retrospective single-centre experience.
   J Antimicrob Chemother. 2024;79:2179-2185.
   PubMed     Abstract available
   
   
   August 2024
8. MEIJS AP, Chaname-Pinedo LE, Deng H, Veldman KT, et al
   Association between antimicrobial usage in livestock and antimicrobial resistance in Escherichia coli isolates from human urinary tract infections in the Netherlands, 2009-2020.
   J Antimicrob Chemother. 2024 Aug 2:dkae268. doi: 10.1093.
   PubMed     Abstract available
   
   
   July 2024
9. WIJNANT GJ, Ngougni Pokem P, Coessens M, Cottone E, et al
   Pharmacokinetics and pharmacological target attainment of standard temocillin dosing in non-critically ill patients with complicated urinary tract infections.
   J Antimicrob Chemother. 2024 Jul 10:dkae215. doi: 10.1093.
   PubMed     Abstract available
   
   
   May 2024
10. TUINTE RAM, van Zanten MD, Takamura T, Schoffelen T, et al
    Follow-up of patients with urinary tract infections discharged from the emergency department: a mixed methods study.
    J Antimicrob Chemother. 2024 May 31:dkae169. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. MENENDEZ ALVARADO LR, Margulis Landayan A, Williams KN, Frederick CM, et al
    Impact of removing ESBL status labelling from culture reports on the use of carbapenems for non-bacteraemic patients diagnosed with ESBL-positive urinary tract infections.
    J Antimicrob Chemother. 2024 May 8:dkae135. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. RECH MA, Faine BA, Gross AE, Vakkalanka P, et al
    Empirical antimicrobial prescribing for pyelonephritis in patients discharged from 15 US Emergency Departments: an opportunity for improvement.
    J Antimicrob Chemother. 2024;79:1038-1044.
    PubMed     Abstract available
    
    
    March 2024
13. HELTVEIT-OLSEN SR, Gopinathan U, Blix HS, Elstrom P, et al
    Effect of methenamine hippurate shortage on antibiotic prescribing for urinary tract infections in Norway-an interrupted time series analysis.
    J Antimicrob Chemother. 2024 Mar 28:dkae078. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2024
14. BAYART J, Drouet J, Peycelon M, Mariani P, et al
    Temocillin for febrile urinary tract infections caused by ESBL-producing Enterobacteriaceae in children: a monocentric exposed/non-exposed study.
    J Antimicrob Chemother. 2024 Feb 27:dkae053. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. PIAZZOLLA HRW, Modin F, Halkjaer SI, Petersen AM, et al
    The association between bacteriuria and adverse pregnancy outcomes: a systematic review and meta-analysis of observational studies.
    J Antimicrob Chemother. 2024;79:241-254.
    PubMed     Abstract available
    
    
    January 2024
16. MONTELIN H, Camporeale A, Hallgren A, Angelin M, et al
    Treatment, outcomes and characterization of pathogens in urinary tract infections caused by ESBL-producing Enterobacterales: a prospective multicentre study.
    J Antimicrob Chemother. 2024 Jan 10:dkad402. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. ARYEE A, Rockenschaub P, Robson J, Ahmed Z, et al
    Assessing the impact of discordant antibiotic treatment on adverse outcomes in community-onset UTI: a retrospective cohort study.
    J Antimicrob Chemother. 2024;79:134-142.
    PubMed     Abstract available
    
    
    December 2023
18. HATTORI Y, Tahara S, Aso S, Makito K, et al
    Comparison of prophylactic antibiotics for endonasal transsphenoidal surgery using a national inpatient database in Japan.
    J Antimicrob Chemother. 2023;78:2909-2914.
    PubMed     Abstract available
    
    
    November 2023
19. KASHOURIS E, Joseph A, Lewis T
    Nitrofurantoin: what is the evidence for current UK guidance?
    J Antimicrob Chemother. 2023;78:2605-2611.
    PubMed     Abstract available
    
    
    
20. TORRES A, Wible M, Tawadrous M, Irani P, et al
    Efficacy and safety of ceftazidime/avibactam in patients with infections caused by beta-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme.
    J Antimicrob Chemother. 2023;78:2672-2682.
    PubMed     Abstract available
    
    
    September 2023
21. NGUYEN HM, Flerchinger S, Smith JR, Felcher AH, et al
    Diagnostic and antibiotic stewardship lessons: an outpatient assessment of symptomatic reflex urinalysis ordering accuracy using an electronic best-practice alert.
    J Antimicrob Chemother. 2023;78:2283-2290.
    PubMed     Abstract available
    
    
    August 2023
22. CARTER C, Hutchison A, Rudder S, Trotter E, et al
    Uropathogenic Escherichia coli population structure and antimicrobial susceptibility in Norfolk, UK.
    J Antimicrob Chemother. 2023;78:2028-2036.
    PubMed     Abstract available
    
    
    July 2023
23. FANSHAWE TR, Judge RK, Mort S, Butler CC, et al
    Evidence-based appraisal of two guidelines for the diagnosis of suspected, uncomplicated urinary tract infections in primary care: a diagnostic accuracy validation study.
    J Antimicrob Chemother. 2023 Jul 4:dkad212. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2023
24. SOJO-DORADO J, Lopez-Hernandez I, Hernandez-Torres A, Retamar-Gentil P, et al
    Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial.
    J Antimicrob Chemother. 2023 Jun 1:dkad147. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. MAHER JM, Huband MD, Blankers CG, Puttagunta S, et al
    In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program.
    J Antimicrob Chemother. 2023;78:1406-1414.
    PubMed     Abstract available
    
    
    May 2023
26. PURCELL R, Yeoh D, Bowen A, Britton PN, et al
    A multicentre, retrospective audit of fosfomycin use for urinary tract infections in Australian children and adolescents.
    J Antimicrob Chemother. 2023 May 16:dkad131. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2023
27. WATKINS RR, Thapaliya D, Lemonovich TL, Bonomo RA, et al
    Gepotidacin: a novel, oral, 'first-in-class' triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea.
    J Antimicrob Chemother. 2023 Mar 8:dkad060. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2023
28. VALLEE M, Harding C, Hall J, Aldridge PD, et al
    Exploring the in situ evolution of nitrofurantoin resistance in clinically derived uropathogenic Escherichia coli isolates.
    J Antimicrob Chemother. 2023;78:373-379.
    PubMed     Abstract available
    
    
    
29. ABBOTT IJ, van Gorp E, Cottingham H, Macesic N, et al
    Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model.
    J Antimicrob Chemother. 2023;78:397-410.
    PubMed     Abstract available
    
    
    January 2023
30. CHEN L, Hua J, Hong SJ, Yuan CY, et al
    Comparison of the relative efficacy of beta-lactam/beta-lactamase inhibitors and carbapenems in the treatment of complicated urinary tract infections caused by ceftriaxone-non-susceptible Enterobacterales: a multicentre retrospective observational coh
    J Antimicrob Chemother. 2023 Jan 24:dkac448. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2022
31. FRIMODT-MOLLER N, Simonsen GS, Larsen AR, Kahlmeter G, et al
    Pivmecillinam, the paradigm of an antibiotic with low resistance rates in Escherichia coli urine isolates despite high consumption.
    J Antimicrob Chemother. 2022;78:289-295.
    PubMed     Abstract available
    
    
    November 2022
32. GUO S, Li X, Li Y, Tong H, et al
    Sitafloxacin pharmacokinetics/pharmacodynamics against multidrug-resistant bacteria in a dynamic urinary tract infection in vitro model.
    J Antimicrob Chemother. 2022 Nov 4. pii: 6795394. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2022
33. WALKTY AJ, Karlowsky JA, Baxter MR, Lagace-Wiens PRS, et al
    In vitro activity of sulopenem against 1880 bacterial pathogens isolated from Canadian patients with urinary tract infections (CANWARD, 2014-21).
    J Antimicrob Chemother. 2022 Sep 30. pii: 6731707. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2022
34. EMERAUD C, Godmer A, Girlich D, Vanparis O, et al
    Activity of mecillinam against carbapenem-resistant Enterobacterales.
    J Antimicrob Chemother. 2022 Jul 11. pii: 6639593. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2022
35. ABBOTT IJ, van Gorp E, Wyres KL, Wallis SC, et al
    Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model.
    J Antimicrob Chemother. 2022;77:1324-1333.
    PubMed     Abstract available
    
    
    
36. FUCHS F, Becerra-Aparicio F, Xanthopoulou K, Seifert H, et al
    In vitro activity of nitroxoline against carbapenem-resistant Acinetobacter baumannii isolated from the urinary tract.
    J Antimicrob Chemother. 2022 Apr 12. pii: 6566767. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2022
37. NEVILLE LF, Shalit I, Warn PA, Rendell JT, et al
    Vancomycin-arginine (STM-001) abrogates ESBL carrier and carbapenem-resistant Escherichia coli burden in a murine complicated urinary tract infection model.
    J Antimicrob Chemother. 2022 Mar 1. pii: 6539950. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Urinary Tract Infection is free of charge.